Spurstone Advisory Services’s Xeris Biopharma Holdings XERS Stock Holding History

Spurstone Advisory Services’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6K	Hold	200	–	–	0.02%	63
2026 Q1	$1.16K	Hold	200	–	–	0.02%	48
2025 Q4	$1.57K	Hold	200	–	–	0.02%	65
2025 Q3	$1.63K	Hold	200	–	–	0.02%	81
2025 Q2	$934	Hold	200	–	–	0.01%	110
2025 Q1	$1.1K	Hold	200	–	–	0.02%	73
2024 Q4	$678	Buy	+200	New	+$643	0.01%	64

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Spurstone Advisory Services's XERS Position: Q2 2026 in Review

Spurstone Advisory Services held its Xeris Biopharma Holdings (XERS) position steady in Q2 2026 at 200 shares worth $1.6K. The position accounts for 0.02% of the portfolio, ranked #63.

Spurstone Advisory Services first reported a position in XERS in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.63K in Q3 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

Spurstone Advisory Services held 200 shares of Xeris Biopharma Holdings worth $1.6K as of Q2 2026.
Spurstone Advisory Services left its Xeris Biopharma Holdings share count unchanged in Q2 2026.
Xeris Biopharma Holdings made up 0.02% of Spurstone Advisory Services's portfolio in Q2 2026, its #63 holding.
Spurstone Advisory Services first reported a position in Xeris Biopharma Holdings in Q4 2024 and has held it in 7 quarters since.
Spurstone Advisory Services's Xeris Biopharma Holdings position peaked at $1.63K in Q3 2025.
240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Spurstone Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.